TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6996816
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg BID cephradine
Study: 6996816
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg BID cephradine
Study: 30628167
Drug: Virgin olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virgin olive oil (10 g d-1)
Study: 30628167
Drug: Whole grain
Normalized name: Whole grain barley
DrugBank: Barley (DB10506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole grain (25 g d-1)
Study: 30628167
Drug: Nuts (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nuts (30 g d-1)
Study: 30628167
Drug: Legumes (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Legumes (25 g d-1)
Study: 30628167
Drug: Fish (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish (25 g d-1)
Study: 27216350
Drug: oxymetazoline plus
Normalized name: oxymetazoline Nasal Spray [Duramist Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxymetazoline plus mometasone furoate nasal spray (MFNS)
Study: 27216350
Drug: placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo plus mometasone furoate nasal spray (MFNS)
Study: 17083910
Drug: 350 mm²
Normalized name: allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 mm² Baerveldt glaucoma implant
Study: 7615107
Drug: Finasteride 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 7.5 mg/d for 9 months
Study: 264923
Drug: Two fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two fluoride tablets daily
Study: 264923
Drug: One fluoride
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One fluoride tablet daily
Study: 264923
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet (control group)
Study: 25632742
Drug: Aripiprazole (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (5 mg, once daily)
Study: 20206777
Drug: Vaginal brachytherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal brachytherapy (VBT) 21 Gy high-dose rate in three fractions or 30 Gy low-dose rate
Study: 3407609
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg beta-carotene
Study: 2378704
Drug: Pressure applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressure applied after injection of heparin
Study: 2378704
Drug: Aspiration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspiration of the syringe prior to injecting heparin
Study: 2378704
Drug: Subsequent injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent injections with pressure applied after injection
Study: 27025688
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy to the quadriceps
Study: 19052401
Drug: Evening primrose
Normalized name: EVENING PRIMROSE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening primrose oil (EPO) 500 mg capsules
Study: 19052401
Drug: Placebo (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (300 mg sunflower oil capsules)
Study: 9184611
Drug: Nefazodone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone (200 mg/day for Days 1-7; 400 mg/day for Days 8-56)
Study: 9184611
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg/day for Days 1-56)
Study: 9184611
Drug: Both Nefazodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both Nefazodone and Fluoxetine
Study: 3513528
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg guanfacine
Study: 3513528
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg guanfacine
Study: 12854359
Drug: Furosemide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (40 mg tablet)
Study: 29219935
Drug: Intrathecal bupivacaine/morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine/morphine (12.5 mg/300 μg)
Study: 29219935
Drug: Sham procedure
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sham procedure and bolus of piritramide (0.1 mg/kg)
Study: 26962830
Drug: G(120-0) ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: G(120-0) ≥ 2.50 mmol/L or G30 ≥ 9.75 mmol/L
Study: 26962830
Drug: High G(120-0)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High G(120-0) and high G30
Study: 22621162
Drug: Peak SE
Normalized name: selenomethionine Se 75
DrugBank: Selenomethionine Se-75 (DB09400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peak SE self‐etch bonding agent
Study: 22621162
Drug: Peak LC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peak LC etch‐and‐rinse bonding agent
Study: 15883748
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (500 mg, bd, 14 days)
Study: 10442299
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate 200 mg i.m. every 2 weeks
Study: 1333518
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (cyclophosphamide 400 mg/m2, doxorubicin 40 mg/m2, and cisplatin 40 mg/m2 for six cycles)
Study: 1333518
Drug: No active
Normalized name: Aveeno Active Naturals
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active treatment (control group)
Study: 1333518
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (CAP)
Study: 4001254
Drug: Social-learning-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social-learning-based treatment
Study: 31509295
Drug: Alpine climate
Normalized name: Alpine strawberry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpine climate treatment
Study: 31509295
Drug: Moderate maritime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate maritime climate treatment
Study: 24889392
Drug: L-ornithine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-ornithine (400 mg/day)
Study: 15982429
Drug: Kinetic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinetic therapy (PediDyne bed)
Study: 15982429
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (manual turning and percussion)
Study: 15982429
Drug: Kinetic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinetic therapy after standard therapy
Study: 12009344
Drug: Desogestrel (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desogestrel (0.15 mg) plus Ethinyl Estradiol (0.030 mg) daily for 21 days followed by a 7-day rest for 12 months
Study: 12009344
Drug: Cyproterone Acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone Acetate (2 mg) plus Ethinyl Estradiol (0.035 mg) daily for 21 days followed by a 7-day rest for 12 months
Study: 9629401
Drug: Propranolol 60
Normalized name: propranolol 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 60 mg/day plus Flunarizine 10 mg/day
Study: 9629401
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (Propranolol, Flunarizine, Both)
Study: 8198246
Drug: Ophthalmic sodium
Normalized name: fluorescein ophthalmic sodium compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic sodium cromoglycate 2% four times daily
Study: 8198246
Drug: Ophthalmic sodium
Normalized name: fluorescein ophthalmic sodium compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic sodium cromoglycate 4% twice daily
Study: 8198246
Drug: Placebo eye-drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo eye-drops twice daily
Study: 8383058
Drug: Propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 80 mg x 2
Study: 2454378
Drug: Carvedilol (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (both doses)
Study: 29090475
Drug: Intense method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intense method for plaque control - daily powered tooth brushing with 1% Chlorhexidine gel
Study: 29090475
Drug: Conventional method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional method for plaque control - daily manual tooth brushing with a standardised commercial toothpaste
Study: 19941334
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of muscle ache and cramps
Study: 12853344
Drug: VAD bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAD bolus (vincristine 0.4 mg i.v., doxorubicin 9 mg/m² i.v., dexamethasone 40 mg p.o. daily for 4 days)
Study: 12853344
Drug: VAD doxil
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAD doxil (vincristine 2 mg i.v., liposomal doxorubicin 40 mg/m² i.v. on day 1, dexamethasone 40 mg p.o. daily for 4 days)
Study: 25480673
Drug: Shenyankangfu tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenyankangfu tablets
Study: 25480673
Drug: losartan potassium
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: losartan potassium 50 mg
Study: 25480673
Drug: losartan potassium
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: losartan potassium 100 mg
Study: 25480673
Drug: Shenyankangfu tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenyankangfu tablets + losartan potassium 50 mg
Study: 25480673
Drug: Shenyankangfu tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenyankangfu tablets + losartan potassium 100 mg
Study: 17715211
Drug: VML-670 (5-HT(1A)
Normalized name: 5-HT
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VML-670 (5-HT(1A) and 5-HT(1D) agonist)
Study: 12528088
Drug: Carvedilol (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (37.5 +/- 13.5 mg/12 h)
Study: 12528088
Drug: Bisoprolol (5.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (5.4 +/- 3.0 mg/d)
Study: 7537286
Drug: Risperidone 6
Normalized name: risperidone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 6 to 16 mg/day
Study: 45068
Drug: Oxytocin induced
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin induced labor using amniotomy and oxytocin infusion with the Cardiff Infusion System Mark II
Study: 28081548
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of bevacizumab with second-line chemotherapy
Study: 21394500
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZOL) 4 mg administered intravenously after each chemotherapy cycle for 60 months post-randomisation (six doses in the first 6 months, eight doses in the following 24 months and five doses in the final 30 months).
Study: 21394500
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received neither additional treatment nor intravenous ZOL.
Study: 14994569
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide inhalation (Group A)
Study: 14994569
Drug: No nitric
Normalized name: Nitric Acid
DrugBank: Nitric acid (DB15995)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No nitric oxide inhalation (Group B)
Study: 10978060
Drug: Hypothermic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermic treatment using the 'forced air' method for 6 hours (cooling blanket with a flow of cool air at 10 degrees C)
Study: 10978060
Drug: Hypothermic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermic treatment
Study: 1739570
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at doses of 1.2, 1.4, 1.6, 1.8, 2.0, 2.2, 2.4, and 2.6 mg kg‐1
Study: 23360359
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (CoQ10) 200 mg/d for 8 weeks
Study: 16540798
Drug: Higher-LCPUFA formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-LCPUFA formula with 17 mg DHA, 34 mg ARA, 85 mg ALA, and 860 mg LA per 100 kcal
Study: 16540798
Drug: Lower-LCPUFA formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-LCPUFA formula with 8 mg DHA, 21 mg ARA, 110 mg ALA, and 1,000 mg LA per 100 kcal
Study: 1591828
Drug: tissue-type plasminogen
Normalized name: Tissue-type plasminogen activator
Approvals — FDA: no, EMA: no, PMDA: no
Description: tissue-type plasminogen activator (100 mg over 2 hours)
Study: 3901674
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication plus cognitive therapy
Study: 30453332
Drug: Short-term intensive
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term intensive (STI) therapy
Study: 30646152
Drug: Trial control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial control strategy (increased cholesterol level monitoring and use of electronic pill bottles)
Study: 22129562
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication combinations (mirtazapine and venlafaxine)
Study: 20012484
Drug: Lubiprostone 24
Normalized name: LUBIPROSTONE 24MCG CAP,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubiprostone 24 mcg twice daily
Study: 18843432
Drug: Resistance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance training combined with coenzyme Q10 supplementation (200 mg/day)
Study: 26872008
Drug: Irinotecan 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 125 mg/m2 and cisplatin 60 mg/m2 (high-dose group)
Study: 26872008
Drug: Irinotecan 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 80 mg/m2 and cisplatin 50 mg/m2 (low-dose group)
Study: 26872008
Drug: Both high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both high-dose and low-dose groups
Study: 23338668
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 4 % spray gel applied two or three times daily for 3 days
Study: 17324628
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of carbohydrates per day
Study: 17324628
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of carbohydrates per day
Study: 12137830
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (urethrocystoscopy)
Study: 8578801
Drug: SPf(66)n synthetic
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPf(66)n synthetic malaria vaccine
Study: 31164156
Drug: Monthly income
Normalized name: Lincomed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly income 1001-2000 Ethiopian birr
Study: 31164156
Drug: Monthly income
Normalized name: Lincomed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly income 2001-3000 Ethiopian birr
Study: 25561337
Drug: Isavuconazole 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isavuconazole 200 mg on day 1 and then 50 mg once daily (arm A)
Study: 25561337
Drug: Isavuconazole 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isavuconazole 400 mg on day 1 and then 400 mg once-weekly (arm B)
Study: 25561337
Drug: Isavuconazole 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isavuconazole 400 mg on day 1 and then 100 mg once daily (arm C)
Study: 25561337
Drug: Fluconazole 200
Normalized name: fluconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 200 mg on day 1 and then 100 mg once daily (arm D)
Study: 21876476
Drug: cinacalcet (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: cinacalcet (30 mg daily)
Study: 19706990
Drug: Exenatide QW
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide QW 0.8 mg
Study: 19706990
Drug: Exenatide QW
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide QW 2.0 mg
Study: 9756250
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g hydrolyzed guar fiber
Study: 7923804
Drug: Alpha-interferon (Alfaferone:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-interferon (Alfaferone: Alfa-Wassermann Bologna, Italy) 3 x 10(6) IU by i.m. injection every other day for four weeks (total of 12 injections)
Study: 31557450
Drug: DXM+ (Dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DXM+ (Dexmedetomidine infusion at 4 μg/kg/hr)
Study: 28800383
Drug: GSK2793660 (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2793660 (12 mg once daily for 21 days)
Study: 28800383
Drug: GSK2793660 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2793660 (single escalating doses from 0.5 to 20 mg)
Study: 23364629
Drug: Oral paricalcitol
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral paricalcitol treatment at doses of 1 mcg/day
Study: 23364629
Drug: 1 ampoule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ampoule calcifediol/wk (0.266 mg/wk=16 000U) orally
Study: 19490137
Drug: Group II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II: verbal instructions and a self-educational manual on oral hygiene without illustrations
Study: 19490137
Drug: Group III:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group III: oral hygiene guidance with verbal instructions and a self-teaching manual
Study: 19490137
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group I: continued personal oral hygiene routine
Study: 17046166
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg oral micronized progesterone
Study: 15301325
Drug: Intensive glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glucose management protocol (continuous intravenous insulin if glucose >200 mg/dL, target glucose <140 mg/dL)
Study: 9152646
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of troponin T and exercise test response (Low risk n = 84)
Study: 9152646
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of troponin T and exercise test response (Intermediate risk n = 406)
Study: 9152646
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of troponin T and exercise test response (High risk n = 276)
Study: 8490912
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin 750 mg plus clindamycin 600 mg every 8 hours
Study: 8490912
Drug: IV aztreonam
Normalized name: Aztreonam
DrugBank: Aztreonam (DB00355)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV aztreonam 2 g plus clindamycin 600 mg every 8 hours
Study: 8490912
Drug: Oral regimen
Normalized name: aspirin Oral Tablet [Anacin Aspirin Regimen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral regimen
Study: 3124734
Drug: Ceftazidime 2
Normalized name: ceftazidime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 2 g intravenously every 12 hours
Study: 27316224
Drug: Intranasal sodium
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal sodium citrate solution
Study: 27316224
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride solution (placebo control)
Study: 25195371
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose Qianlongtong Capsule (6 capsules once, tid for 7 days)
Study: 25195371
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose Qianlongtong Capsule (3 capsules once, tid for 7 days)
Study: 25195371
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Qianlongtong Capsule (1.5 capsules once, tid for 7 days)
Study: 15801915
Drug: Rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 10 mg continuous treatment (once daily)
Study: 12451189
Drug: IFNbeta‐1a 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNbeta‐1a 30 micro g IM once weekly
Study: 12451189
Drug: IFNbeta‐1a 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNbeta‐1a 60 micro g IM once weekly
Study: 11019837
Drug: CD34+ cell
Normalized name: CD34+ Cells
DrugBank: Autologous peripheral blood-derived CD34+ cells (DB16367)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD34+ cell dose >=2 x 10(6)/kg
Study: 9260226
Drug: Ferric sulfate
Normalized name: Ferric Sulfate
DrugBank: Ferric sodium citrate (DB13771)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferric sulfate (FS) solution for 15 sec, rinsed, and covered by zinc oxide‐eugenol paste (ZOE)
Study: 3549399
Drug: New trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: New trivalent vaccine produced exclusively on human tissue
Study: 3549399
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available M-M-R-II vaccine produced by MSD
Study: 23051991
Drug: NA-1 (Tat-NR2B9c)
Normalized name: sodium 1-naphthalenesulfonate
DrugBank: Nerinetide (DB12595)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NA-1 (Tat-NR2B9c) intravenous infusion
Study: 18705272
Drug: 50mg diacerein
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg diacerein tablets administered twice daily for 12 weeks
Study: 20345617
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 mL saline)
Study: 31791333
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D fortified foods (30 μg vitamin D3/day through fortified yoghurt, cheese, eggs, and crisp-bread)